Brought to you by 
Covagen partners bispecific FynomAbs with Mitsubishi Tanabe Pharma
07 Feb 2014
Executive Summary
Large-molecule cancer and inflammation therapeutics developer Covagen AG has granted Mitsubishi Chemical Holdings Corp.’s Mitsubishi Tanabe Pharma Corp. an exclusive worldwide license to develop, manufacture, and sell its bispecific FynomAbs against up to two target pairs chosen by Mitsubishi Tanabe and its US biological drug discovery division Tanabe Research Laboratories USA Inc. (TRL).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Covagen partners bispecific FynomAbs with Mitsubishi Tanabe Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice